Hepatitis C Virus Core Protein Induces Cell Proliferation and Activates ERK, JNK, and p38 MAP Kinases Together with the MAP Kinase Phosphatase MKP-1 in a HepG2 Tet-Off Cell Line  by Erhardt, Andreas et al.
Virology 292, 272–284 (2002)
doi:10.1006/viro.2001.1227, available online at http://www.idealibrary.com onHepatitis C Virus Core Protein Induces Cell Proliferation and Activates ERK, JNK, and p38
MAP Kinases Together with the MAP Kinase Phosphatase MKP-1 in a HepG2 Tet-Off Cell Line
Andreas Erhardt,1 Mohamed Hassan, Tobias Heintges, and Dieter Ha¨ussinger
Klinik fu¨r Gastroenterologie, Hepatologie, und Infektiologie, Heinrich-Heine-Universita¨t Du¨sseldorf,
Moorenstrasse 5, D-40225 Du¨sseldorf, Germany
Received February 13, 2001; returned to author for revision May 11, 2001; accepted October 11, 2001
Hepatitis C virus (HCV) core protein is a multifunctional protein interacting with cellular and viral proteins and promoters.
A tetracycline-regulated system was used to generate a HepG2 Tet-Off cell line allowing regulated expression of a full-length
(191 aa) and an Nc-truncated core protein (160 aa). In this system HCV core protein expression activates extracellular
signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK), and p38 mitogen-activated protein (MAP) kinase, induces MAP
kinase phosphatase MKP-1 expression, and increases cell proliferation. This was accompanied by an activation of c-Jun and
ATF-2, but not Elk-1 and c-Fos. Furthermore, AP-1 activation was independent of c-Fos. Full-length and Nc-truncated HCV
core proteins exerted similar effects. © 2002 Elsevier Science
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Hepatitis C virus (HCV) infection is a common disease,
affecting about 3% of the world population (WHO, 1997).
Hepatitis C accounts for approximately 20% of cases of
acute hepatitis and 70% of cases of chronic hepatitis.
Chronic hepatitis C is a major cause of liver cirrhosis and
hepatocellular carcinoma (Marcellin, 1999).
HCV is a member of the Flaviviridae family and was
first isolated in 1989. The positive-strand RNA genome
contains a large open reading frame of about 9.5 kb
encoding a large precursor polyprotein, which is cleaved
by both cellular and viral proteases into structural and
nonstructural proteins (Choo et al., 1989). Core protein is
encoded at the 59-terminal region of the ORF and is
composed of a basic, RNA-binding amino-terminal do-
main and a highly hydrophobic carboxy-terminal region
(Santolini et al., 1994). Mature 21-kDa HCV core protein is
produced by cleavage between aa 191 and 192 of the
precursor polyprotein. HCV core protein products of 19
and 16 kDa have further been described (Santolini et al.,
1994). The core protein is associated with the cytoplas-
mic side of the endoplasmic reticulum (Hijikata et al.,
1991; Santolini et al., 1994) but has also been detected in
the nucleus (Lo et al., 1995).
In addition to encapsidation of viral RNA, recent stud-
ies have suggested a possible role of the HCV core
protein in host cell growth, apoptosis, and carcinogene-
sis. The transforming potential of the HCV core protein1 To whom correspondence and reprint requests should be ad-
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272has been demonstrated in rat embryo fibroblasts (Chang
et al., 1998; Ray et al., 1996a) and transgenic mice
(Moriya et al., 1998). In vitro studies suggested that the
HCV core protein has regulatory functions acting as
either a trans-activator or a trans-suppressor for different
cellular and viral genes (Ray et al., 1997, 1998; Srinivas et
al., 1996; Shih et al., 1995). Pro- and anti-apoptotic func-
tions of the HCV core protein have been reported (Ray et
al., 1996b; Ruggieri et al., 1997; Marusawa et al., 1999).
However, the precise role of the HCV core protein in
apoptotic cell death is still unclear. Furthermore, the HCV
core protein has been shown to interact with apolipopro-
tein II, tumor necrosis factor (TNF) receptor lymphotoxin
b-receptor, 14-3-3 protein, DEAD box protein DD3, and
heterogeneous ribonucleoprotein K (Aoki et al., 2000;
Zhu et al., 1998; Hsieh et al., 1998; Matsumoto et al., 1997;
Owsianka and Patel, 1999; Sabile et al., 1999).
Although it is likely that the HCV core protein has an
important role in the regulation of cell growth, apoptosis,
or carcinogenesis, the mechanisms by which the HCV
core protein influences these processes remain to be
determined. The MAP (mitogen-activated protein) kinase
cascade has emerged as a key signaling pathway reg-
ulating cell growth, differentiation, and transformation
through intracellular phosphorylation (Lewis et al., 1998;
Schmidt et al., 1997; Mansour et al., 1994). In mammalian
cells, three distinct subtypes of MAP kinase pathways
have been identified, all sharing a threonine-X-tyrosine
phosphorylation motif: extracellular signal-regulated ki-
nase (ERK), c-jun N-terminal kinase (JNK), and p38
MAPK.
We investigated the potential role of the HCV core
273HCV CORE PROTEIN ACTIVATES MAP KINASESprotein in the intracellular signal transduction pathway of
MAP kinases. In order to analyze the effect of the HCV
core protein on the MAP kinase signaling pathway at
different expression levels we established a HepG2 Tet-
Off cell line with regulated expression of the HCV core
protein. The HepG2 Tet-Off cell line is based on regula-
tory elements of the tetracycline-resistance operon of
Escherichia coli with a tetracycline-controlled transacti-
vator (tTa) and a tTA-dependent promoter which is virtu-
FIG. 1. Tetracycline regulated HCV core expression in HepG2 Tet-O
HepG2-160-B cultured in the presence of 0, 2, 4, 6, or 8 mg/ml of tetrac
described under Materials and Methods. The equal loading of mRNA w
160 and 191 were detected in total RNA isolated from HepG2 tran
HepG2-191-1B and HepG2-160-B and pBI-L transfected control cells, c
12% SDS–PAGE and analyzed by immunoblotting using a polyclonal aally silent in the presence of tetracycline and is activated
in the absence of tetracycline (Gossen and Bujard, 1992).RESULTS
Characterization of HepG2 Tet-Off with regulated
expression of HCV core proteins and control cells
Inducibility and expression of the HCV core gene was
determined by luciferase activity, Northern blot analysis
(Fig. 1A), Western blot analysis, and reverse transcrip-
tion-polymerase chain reaction (RT-PCR) (Fig. 1B).
Twelve hours after withdrawal of tetracycline, induction
s. (A) 20 mg of cellular RNA isolated from clones HepG2-191-1B and
was analyzed for HCV core transcription by Northern blot analysis as
rmined by GAPDH (not shown). (B) The mRNA transcripts of HCV core
nts by RT-PCR. Protein lysates (100 mg) prepared from the clones
in the presence or in the absence of tetracycline, were separated by
core antibody.ff cell
ycline
as dete
sfecta
ultured
nti-HCVrates of about 1:370 were found for both the HepG2 clone
191-1B and the HepG2 clone 160-B. In time course ex-
274 ERHARDT ET AL.periments a significant increase in luciferase activity
was observed 30–40 min after withdrawal of tetracycline.
In all experiments a baseline level of HCV core expres-
sion was maintained that could not be suppressed fur-
ther by increasing tetracycline concentrations.
HepG2 Tet-Off cells (pBI-L) with a luciferase gene under
control of a CMV minimal promoter without the HCV core
insert were taken as controls for all experiments.
Measurement of cytotoxicity and cell proliferation
In all cells expressing HCV core proteins, a significant
FIG. 2. Effect of HCV core on cell proliferation. (A) [3H]Thymidine up
Measurement of cell proliferation by MTT assay in the presence (1)
deviation of six independent experiments are given. *P value , 0.001.induction of cell proliferation was noticed as determined
by [3H]thymidine uptake (Fig. 2A). [3H]Thymidine uptakeand MTT (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazo-
lium bromide) metabolism were more pronounced in
cells with high HCV core protein expression than in cells
with low HCV core protein expression (Figs. 2A and 2B).
The activities of LDH (lactate dehydrogenase) in the cell
culture supernatant were taken as an indicator of cyto-
toxicity. No significant differences were noticed between
control cells and cells expressing the HCV core protein
independent of the addition of tetracycline. Tetracycline
itself did not alter cell viability (not shown) and was
without effect on [3H]thymidine uptake in control cells
the presence (1) and in the absence (2) of 8 mg/ml tetracycline. (B)
the absence (2) of 8 mg/ml tetracycline. Mean values and standardtake in
and in(12,070 6 1563 cpm for control cells with tetracycline and
11,090 6 310 cpm for cells without tetracycline; ns).
275HCV CORE PROTEIN ACTIVATES MAP KINASESEffect of HCV core protein on the activity and protein
expression of MAP kinases (JNK, ERK, and p38)
As shown in Figs. 3A–3C withdrawal of tetracycline
from the culture medium for 12 h led to a 3.7 6 0.2-, 4.2 6
0.8-, and 2.8 6 0.2-fold increase of the basal activity of
JNK, ERK, and p38 in the clone HepG2-191-1B and a
4.1 6 0.2-, 4.2 6 0.9-, and 2.8 6 0.1-fold increase in the
clone HepG2-160-B when compared to the control cells.
The HCV core proteins 191 and 160 induced protein
expression of JNK and p38 1.9 6 0.1- and 1.8 6 0.2-fold
(clone HepG2-191-1B) and 2.1 6 0.1- and 2.0 6 0.2-fold
(clone HepG2-160-B) compared to the control cells. No
significant increase was observed in the protein expres-
sion of ERK1/2 either in the clone HepG2-191-1B or in the
clone HepG2-160-B compared to control cells. No signif-
icant effect of tetracycline itself was observed on JNK,
ERK, or p38 MAP kinase activity in control cells.
Effect of HCV core protein on proto-oncogenes c-Jun
and c-Fos
In the absence of tetracycline, mRNA expression of
c-jun in the clones HepG2-191-1B and HepG2-160-B in-
creased 5.9 6 0.8- and 6.1 6 0.6-fold by 12 h, compared
to control cells (Fig. 4A). In immunoblot analysis, the
protein expression remained unchanged in control cells
within 3 to 12 h, whereas a 8.2 6 1.5- and 9.2 6 2.2-fold
increase in the protein expression after the withdrawal of
tetracycline from the culture medium was noted within
12 h in the clones HepG2-191-1B and HepG2-160-B (Fig.
4A). Withdrawal of tetracycline from the culture medium
did not induce significant changes at the mRNA or pro-
tein level of c-Fos compared to control cells (Fig. 4B).
Effect of HCV core protein on AP-1 activity
Withdrawal of tetracycline increased the basal activity
of the transcription factor AP-1 within 12 h by 5.2 6 1.2-
and 4.9 6 0.9-fold in the clones HepG2-191-1B and
HepG2-160-B compared to control cells (Fig. 5A). There
was no effect of tetracycline itself on AP-1 activation in
control cells: the absolute ODs were 14,428 6 1552
(pBI-L without tetracycline) and 14,712 6 1250 (pBI-L with
tetracycline). The authenticity of the AP-1 band following
incubation of the nuclear extracts with antibodies raised
against c-Jun and c-Fos proteins was ascertained by
supershift assay. Antibodies against the c-Jun protein
shifted the band to a higher molecular mass, whereas
antibodies to c-Fos did not shift the AP-1 band (Fig. 5B).
Effect of HCV core protein on Elk-1, ATF-2, and NF-kB
activation
Elk-1 activation was tested by EMSA using an SRE
(serum response element)-specific sequence with
HepG2 cells grown in the presence (8 mg/ml) and ab-sence of tetracycline. No significant changes in the ac-
tivity of the transcription factor Elk-1 were seen. The
activity of the transcription factor ATF-2 was investigated
by EMSA with a CRE-specific sequence. The withdrawal
of tetracycline from the culture medium significantly in-
creased the basal activity of ATF-2 in the clone HepG2-
191-1B and in the clone HepG2-160-B 3.9 6 0.2- and
3.6 6 0.4-fold compared to control cells (Fig. 6). IL-1
stimulated NF-kB expression was reduced in all cells
expressing HCV core protein when compared to controls
(Fig. 7). Some effect of tetracycline was found in both
control and HCV core expressing cells.
Effect of HCV core protein on MKP-1 expression
Northern blot analysis revealed a significant induction
of MKP-1 (5.8 6 1.7 and 4.1 6 0.9) in HepG2-191 and
HepG2-160 cells compared to control cells after with-
drawal of tetracycline (Fig. 8). The increase in mRNA
levels in HepG2 core transfected cells went in line with
a marked increase in the protein levels of MKP-1, reach-
ing a mean induction of 6.2 6 2.7 (HepG2-191) and 4.8 6
1.8 (HepG2-160) 12 h after withdrawal of tetracycline.
DISCUSSION
Protein kinases and phosphatases play a key role in
the regulation of cell growth. There is increasing evi-
dence that the development of hepatocellular carcinoma
might be associated with activation of the Ras/Raf/MAP
kinase pathway (Ito et al., 1998; Schmidt et al., 1997). On
the other hand, there are numerous clinical and in vitro
studies suggesting an important role of the HCV, espe-
cially of the HCV core protein, in liver carcinogenesis
(Moriya et al., 1998; Ray et al., 1996a, 2000; Chang et al.,
1998). Thus one may speculate that the HCV core protein
plays a key role in the development of human liver
disease through activation of the MAP kinase pathway.
Indeed, activation of ERK MAP kinases has been re-
ported for the HCV core protein (Hayashi et al., 2000).
However, the influence of the HCV core protein on MAP
kinases and the influence of MAP kinases on disease
progression are not fully understood. Major findings of
the study presented here are the increased cell prolifer-
ation in HepG2 Tet-Off cells stably transfected with HCV
core proteins. Furthermore an activation of ERK, JNK, and
p38 MAP kinases and MKP-1 was found. The Tet-Off
system was established in order to investigate the ef-
fects of the HCV core proteins even at low expression
levels. However, even in the Tet-Off system, HCV core
protein overexpression cannot be ruled out.
Although transforming and anti-apoptotic properties
have been attributed to the HCV core protein alone or in
synergy with H-ras (Chang et al., 1998; Jin et al., 2000;
Ray et al., 1996a), cell proliferation has not yet been
studied. Increased cell proliferation was found in the
present study for HepG2 cells expressing HCV core
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277HCV CORE PROTEIN ACTIVATES MAP KINASESproteins compared to control cells. The transcription
factor AP-1 plays a key role in cell proliferation (Leppa
and Bohmann, 1999). In line with previous studies (Kato
et al., 2000; Shrivastava et al., 1998) a strong activation of
AP-1 by the HCV core protein was found. Activation of
FIG. 4. Effect of HCV core protein on the expression of c-jun (A) and
from the clones HepG2-191-1B and HepG2-160-B cultured in the abs
empty-vector (pBI-L) transfected control cells, harvested at 3, 6, and
Materials and Methods. The equal loading of RNA was determined by
were taken as reference. A representative blot and the mean inductio
FIG. 3. Effect of HCV core protein on MAP kinase (JNK, p38, and ER
activity (C) were measured by immune complex kinase assay with GS
HepG2-160-B and the empty-vector (pBI-L) transfected control cells wer
and mean inductions of four (JNK) and three (ERK and p38) independ
protein expression is shown by gray bars. For calculation of kinase activity an
The total protein expression was determined by Western blot analysis usingAP-1 was accompanied by an induction of the proto-
oncogene c-Jun at the protein and mRNA levels.
Although the ERK cascade plays an important role in
the regulation of cell growth and differentiation (Krontiris,
1995) its contribution to HCV core-induced cell prolifer-
). Twenty micrograms of total RNA and 50 mg nuclear extract isolated
Tc) and in the presence of (1Tc) of 8 mg/mL tetracycline and from
ere analyzed by Northern blot and Western blot as described under
. For calculation of gene and protein induction, empty-vector controls
e (c-jun) and three (c-fos) independent experiments are given.
ivity and protein expression. JNK activity (A), ERK activity (B), and p38
or myelin basic protein as substrate. The clones HepG2-191-1B and
ared as described under Materials and Methods. A representative blot
eriments are given. Kinase activity is represented by black bars, andc-fos (B
ence (2
12 h, wK) act
T–c-Jun
e prep
ent exp
d protein expression, empty-vector controls were taken as references.
specific antibodies as mentioned under Materials and Methods.
contro
278 ERHARDT ET AL.ation appears unlikely. This is supported by the finding
that HCV core-induced ERK activation was not accom-
panied by activation of c-Fos or Elk-1. Further, c-Fos
protein was not required for the formation of the AP-1
complex. The present results based on the investigation
of the endogenous SRE/Elk-1 activity are in contrast to
studies using a reporter assay demonstrating a signifi-
cant increase of the Elk-1 activity (Hayashi et al., 2000;
Kato et al., 2000). However, the possibility cannot be
FIG. 5. Effect of HCV core protein on AP-1 activation. (A) Nucle
double-stranded AP-1-specific sequence as described under Materials
the presence of 8 mg/ml tetracycline (1) and in the absence of tetrac
independent experiments are given as means and SEM. Empty-vector
specific antibodies to c-Jun or c-Fos.excluded that HCV core proteins influence degradation
of Elk-1 and c-Fos proteins as degradation of c-Fos isinfluenced by MAP kinases, c-Jun, and cell growth (Sal-
vat et al., 1999; Papavassiliou et al., 1992). There is
evidence that the kinetics of ERK activation drives cells
toward either proliferation (transient activation) or differ-
entiation (sustained activation) (Cowley et al., 1994). A
long-lasting activation (12 h) was found in our cells,
supporting further the idea that ERKs are not the main
mediators for cell proliferation in our HepG2 cells.
Increased cell proliferation may also be due to activa-
acts (4 mg) were incubated with 8 fmol of [g-32P]ATP end-labeled
ethods. Control cells and HCV core DNA transfected cells cultured in
2) were analyzed for AP-1 activity by gel-shift assay. Results of three
ls were taken as references. (B) Supershift assay was performed withar extr
and M
ycline (tion of ATF-2, as seen in our study. It has been reported
that ATF-2 might interact with the AP-1 complex and
F-2 act
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1995). ATF-2 is activated by p38 MAP kinase, which was
induced in our HCV core transfected HepG2 cells. Be-
sides the activation of ATF-2, cytosolic phospholipase
A2, and MAP kinase-activated protein (MAPKAP), p38
FIG. 6. Effect of HCV core protein on Elk-1 and ATF-2 activation. Fou
pBI-L empty vector (controls), pBCore160, and pBCore191 cultured in th
were analyzed by gel-shift assay with 8 fmol of [g-32P]ATP end-labeled
described under Materials and Methods. For calculation of Elk-1 and AT
and SEM of three independent experiments are given.
FIG. 7. Effect of HCV core protein on NF-kB activation. HepG2 Tet-Off
cells stably transfected with pBI-L empty vector (controls), pBCore160,
and pBCore191 cultured in the presence of 8 mg/ml tetracycline (1) and
in the absence of tetracycline (2). HepG2 cell were preincubated for
12 h with 50 U/liter IL-1. Nuclear extracts were investigated for NF-kB
activation by EMSA.MAP kinase plays an important role during liver regen-
eration (Spector et al., 1997). The p38 MAPK is further
known to be activated in response to inflammatory sig-
nals, cell hydration, and stress and plays a role in cell
repair, apoptosis, proteolysis, cell cycle regulation, and
activation of immune responses (Kyriakis and Avruch,
1996; Ha¨ussinger et al., 1999). Although p38 MAPK might
contribute to enhanced cell proliferation, the role of p38
MAPK in hepatitis C virus infection remains to be further
elucidated. One interesting feature might be a modula-
tion of the JAK/STAT pathway by the HCV core protein via
p38 MAPK activation and upregulation of SOCS (sup-
pressors of cytokine signaling) (Bode et al., 1999). The
JAK/STAT signal transduction pathway plays an impor-
tant role in mediating interferon signaling (Darnell, 1997).
The MAP kinase phosphatase MKP-1 is an immediate-
early gene able to dephosphorylate phosphoserine/thre-
onine as well as phosphotyrosine residues. There is
evidence that MKP-1 inhibits apoptosis via preferential
inactivation of JNK/p38 MAP kinases and to a lesser
degree via ERKs (Magi-Galluzzi et al., 1998), suggesting
a role of MKP-1 in cell proliferation and carcinogenesis.
MAP kinase activity results from the kinase/phosphatase
balance (Camps et al., 2000). A simultaneous activation
of MAP kinases and MKP-1 was observed in our cells.
The simultaneous activation of MAP kinases and MKP-1
suggests that MKP-1 induction may not be sufficient for
inactivation of MAP kinases in Hep G2 cells. A different
cellular localization of MKP-1 (nuclear localization) and
MAP kinases, which are found in the nucleus and the
grams of nuclear extract of HepG2 Tet-Off cells stably transfected with
nce of 8 mg/ml tetracycline (1) and in the absence of tetracycline (2)
-stranded SRE-specific or CRE-specific sequence for Elk-1 or ATF-2 as
ivation, empty-vector controls were taken as references. Fold inductionr micro
e prese
doublecytoplasm, might be a further possible explanation. It has
been shown in addition that ERK-1,2 can function as
scribed
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MKP-1 and increasing the half-life of MKP-1 (Brondello et
al., 1997, 1999). Given this complexity, kinetic studies will
be required to clarify the function of MKP-1 in its interplay
with MAP kinases.
It has been demonstrated that accumulation of viral
proteins can induce an endoplasmic reticulum (ER) over-
load response and thus interfere nonspecifically with
intracellular signal transduction pathways (Pahl and
Baeuerle, 1995). ER overload requires the activation of
NF-kB. As NF-kB activation was reduced upon expres-
sion of the HCV core protein in our HepG2 cells an
activation of MAP kinases due to ER overload seems
unlikely.
Different HCV core protein products have been de-
scribed with molecular masses of 21, 19, and 16 kDa (Lo
et al., 1995). Due to a localization of the proteins at the
endoplasmic reticulum (p21, p19) and in the nucleus
(p16), different biological functions have been proposed.
However, in the present study only qualitative differ-
ences were found for full-length and Nc-truncated HCV
core proteins with regard to MAP kinase signals.
MATERIALS AND METHODS
Plasmid constructs
The plasmid pcDNA3 (a gift from J. Wands, Providence,
RI) containing the entire HCV-1b core genomic region
was used as template in a standard PCR to amplify the
FIG. 8. Effect of HCV core protein on the expression of MKP-1. Tw
HepG2-160-B cultured in the absence (2Tc) and in the presence of (1
cells was analyzed by Northern blot as described under Materials and
(50 mg) were analyzed by Western blot with specific antibodies as de
empty-vector controls were taken as references. Mean induction levelfull-length HCV core (aa 1–191) and the 39-end truncated
HCV core (aa 1–160) by using the oligonucleotide senseprimer 59-CCC AAG CTT GGG ACC ATG AGC ACG AAT
CCC and the antisense primers 59-CCC AAG CTT GGG
GTC CTC CAG AAC CCG GA-39 (HCV core 160) and
59-CCC AAG CTT GGG CGG GGA AGC TGG AAT GG-39
(HCV core 191) with integrated restriction sites of the
restriction enzyme HindIII. The digested DNA fragments
were inserted into the HindIII site of the pBI-L vector
(Clontech, Palo Alto, CA) using standard cloning proce-
dures (Fig. 9) (Sambrook et al., 1989). The pBI-L vector
contains a bidirectional tTA-dependent promoter (in Fig.
9, TRE denotes tetracycline-responsive element) allow-
ing the regulated expression of a luciferase reporter
gene and the gene of interest. The constructed plasmids
were transformed into E. coli Top F910 (Invitrogen, NV
Leek, The Netherlands) according to standard methods
(Sambrook et al., 1989) and the resulting clones were
sequenced using the primer pair B-IL sense (59-CAAT-
TCGAGCTCGGTACCCG) and B-IL antisense (59-CAA-
GGGTCCCCAAACTCACC) by direct cycle sequencing
with dye-labeled dideoxynucleotides according to the
manufacturer’s instructions (Perkin–Elmer, Foster City,
CA) on an ABI Prism 310 sequencer.
Establishment of HepG2 Tet-Off cell lines
HepG2 is a well-characterized human cell line (Amer-
ican Tissue Culture Collection HB 8065, Rockville, MD).
In order to develop a Tet-Off cell line from the HepG2
cells, about 40 mg of the regulator plasmid pTet-Off was
icrograms of total RNA isolated from the clones HepG2-191-1B and
8 mg/ml tetracycline and from empty-vector (pBI-L) transfected control
ds. The equal loading of RNA was judged by GAPDH. Protein lysates
under Materials and Methods. For calculation of MKP-1 expression
e independent experiments are given.enty m
Tc) of
Methomixed together with the cell suspension at a density of
2 3 106 cells/ml and electroporated in the Easyject Plus
rt of 19
1, HCV
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1050 mF and 260 V (t 5 20 ms). The cells were allowed
to divide twice before the addition of geneticine (400
mg/ml; Gibco BRL, Grand Island, NY) to the culture for
selection. After transient transfection with the pBI-L vec-
tor 16 of 30 clones displayed luciferase activity upon
withdrawal of tetracycline. Clones with the best signal-
to-noise ratio were chosen for the development of a
double stable Tet-Off cell line by cotransfection with the
constructs pTK-Hyg and pBCore160, pBCore191, or pBI-L.
After 48 h cells were selected by addition of hygromycin
at a concentration of 300 mg/ml. Tetracycline was added
to the medium in order to suppress the expression of the
HCV core protein during the selection process. Resistant
colonies were transferred to individual wells and
screened for expression of the HCV core protein by
luciferase assay. Screening of 40 HepG2–Tet-Off clones
(stably-transfected with the plasmids pBcore191 and pB-
core160 comprising the cDNA encoding regions for the
full-length HCV core protein 191 and carboxy-terminal
truncated HCV core 160, respectively) revealed 21 posi-
tive clones, 8 of which allowed inducible expression of
HCV core protein 191 and 11 of which allowed inducible
expression of HCV core protein 160, as assessed by
luciferase assay. Clones termed HepG2-191-1B and
HepG2-160-B showed the best signal-to-noise ratios,
were characterized further, and were chosen for the
subsequent experiments. HepG2 cells stably transfected
with the pBI-L vector without the HCV core insert were
used as controls for all experiments.
Luciferase assays
Luciferase assays were performed according to the
manufacturer’s instructions (Promega, Madison, WI). Rel-
FIG. 9. Schematic representation of the plasmid constructs used fo
with HCV core insert of 160 aa; pBcore191, vector with HCV core inse
cytomegalovirus minimal promoter; MCS, multiple cloning site; Core19ative light units (RLU) were measured in an illuminom-
eter (EG&G, Berthold, Germany).Measurement of cell proliferation and cytotoxicity
Measurement of cell viability and proliferation was
performed by [3H]thymidine uptake assay and in addition
by the MTT assay (Roche Diagnostics, Basel, Switzer-
land) according to the manufacturer’s instructions. The
MTT assay is based on the reduction of tetrazolium salt
by viable cells. The reaction produces a water-insoluble
formazan salt, which must be solubilized by a suitable
solvent. Reduced MTT was assessed at A450 nm–A620 nm
using an ELISA reader (Anthos Reader 2001, Labortec
Instruments, Salzburg, Austria). Experiments were re-
peated six times.
For thymidine uptake, HepG2 Tet-Off cells, cultured in
the presence or in the absence of tetracycline, were
incubated with 0.5 mCi [3H]thymidine for 24 h. [3H]Thy-
midine incorporation after incubation with 5% TCA and
washing was determined by liquid scintillation using a
Microbeta Trilux 1450 plate reader (EG&G Wallac, Turku,
Finland). Experiments were repeated six times.
Cytotoxicity was determined by measurement of LDH
release. The LDH activity was determined according to
the manufacturer’s protocol in five separate experiments
(Roche Diagnostics).
RT-PCR
First-strand cDNA was made using the first cDNA
synthesis kit (Roche Diagnostics) by mixing 2 mg of
denatured total RNA with 5 pmol of specific antisense
primer (160-AS, 59-CCCAAGCTTGGGGTCCTCCAGAAC-
CCGGA, and 191-AS, 59-CCCAAGCTTGGGCGGG-
GAAGCTGGAATGG). Reverse transcription was carried
out in a total volume of 20 ml under standard conditions
using 20 U AMV reverse transcriptase with an incubation
at 25°C for 10 min and 42°C over 60 min. PCR was
ection of HepG2 Tet-Off cells. pBI-L, control vector; pBcore160, vector
1 aa; Luc, luciferase; TRE, tetracycline responsive element; CMVmin,
core insert of 191 aa; Core 160, HCV core insert of 160 aa.r transfperformed in a total volume of 100 ml containing 5 ml of
the first-strand cDNA mix, 2.5 U Taq polymerase (Sigma,
282 ERHARDT ET AL.St. Louis, MO), 0.2 mM dNTP mix, 20 pmol specific
primers, and 13 PCR supplied PCR buffer. For genera-
tion of the HCV core 160-nt fragment and the HCV core
191 fragment, the combination of the sense primer 59-
AACATGACCACGAATCCC with either the antisense
primer 59-CTCCTCCAGAACCCGGA or the antisense
primer 59-CGGGGAAGCTGGAATGG was used.
Northern blotting
Total RNA was isolated from HepG2 cells using the
RNeasy Total RNAMini Kit according to the manufactur-
er’s protocol (Qiagen, Hilden, Germany). RNA separation
was carried out by denaturing agarose gel electrophore-
sis [1.2% agarose, 12.3% formaldehyde, 20 mM MOPS–
acetate (pH 7.0), 1 mM EDTA, 0.5% ethidium bromide]
according to standard protocols (Sambrook et al., 1989).
RNA was transferred to nylon membranes (Hybond-N
nylon membranes, Amersham Pharmacia Biotech,
Braunschweig, Germany) by the capillary elution method
in 7.5 mM NaOH and fixed at 80°C for 2 h. The mem-
branes were hybridized with [a-32P]dCTP 59random la-
beled (approximately 106 cpm/ml) specific cDNA probes
in 50% formamide, 0.25 M NaPO4 (pH 7.2), 0.25 M NaCl,
1 mM EDTA, 7% SDS, and 200 mg/ml salmon sperm DNA
at 43°C overnight. After being washed twice with 23
SSC and twice with 13 SSC, blots were exposed to
Kodak AR X-Omat films at 270°C with intensifying
screens. The loading of RNA was determined by GAPDH.
Specific signals of at least three independent experi-
ments were analyzed by Reytest software (Reytest,
Straubenhardt, Germany).
Western blotting
Cells were washed twice with cold PBS and lysed by
lysis buffer containing 25 mM HEPES (pH 7.5), 0.3 M
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 20 mM
b-glycerolphosphate, 0.1 mM sodium orthovanadate,
0.1% Triton X, and a protease inhibitor cocktail (Roche
Diagnostics). Separation of proteins was carried out by
SDS–polyacrylamide gel electrophoresis (10–15% gel)
according to standard protocols (Sambrook et al., 1989).
Transfer of protein to nitrocellulose membranes (Schlei-
cher & Schuell, Dassel, Germany) from SDS–PAGE was
accomplished in a Hoefer TE 62X Transphor II unit.
Membranes were blocked with TBS (Tris-buffered saline)
buffer with 5% bovine serum albumine (BSA) overnight at
4°C. Blots were incubated with the primary antibody of
interest at a concentration of 1:200 to 1:5000 in TBS
buffer containing 1% BSA and 0.1% Tween 20. The pri-
mary antibodies were directed against c-Fos (Sc-2356,
Santa Cruz Biotechnologies, Santa Cruz, CA), c-Jun (Sc-
44, Santa Cruz Biotechnologies), ERK-1,2 (Sc-44, Santa
Cruz Biotechnologies), JNK-1 (SC-474, Santa Cruz Bio-
technologies), p38 MAPK (Sc-535, Santa Cruz Biotech-
nologies), and MKP-1 (Sc-1102, Santa Cruz Biotechnolo-gies). The polyclonal anti-HCV core antibody was a gift
from Dr. Bartenschlager (University of Mainz). After being
washed in TBS–0.1% Tween, blots were incubated with
horseradish peroxidase-conjugated antibodies (Santa
Cruz Biotechnologies) at a concentration of 1:2000 to
1:30,000 at RT for 1 h. Specific signals were detected by
use of the ECL Western blotting reagents (Amersham
Pharmacia Biotech, Braunschweig, Germany). Blots were
exposed to Kodak AR X-Omat films for 1–5 min. Experi-
ments were performed at least three times.
Immune complex MAP kinase assays
HepG2 cells were lysed in a buffer containing 20 mM
HEPES, pH 7.5, 10 mM EGTA, 40 mM b-glycerolphos-
phate, 25 mM MgCl2, 2 mM sodium orthovanadate, 1 mM
DTT, and 1% NP-40. The cell lysate was transferred to a
microcentrifuge tube and centrifuged for 15 min at 15,000
rpm at 4°C. Aliquots of the supernatant containing 100
mg protein were incubated with 2 mg of an antibody
against ERK-1,2, JNK-1, or p38 MAPK for 1 h at 4°C,
respectively. The sample was mixed with 20 ml of aga-
rose conjugate (Protein A–agarose, Protein G PLUS–
agarose, or Protein A/G PLUS–agarose) and allowed to
incubate at 4°C under constant agitation overnight. The
immunoprecipitates were collected by centrifugation at
1000 rpm for 3 min at 4°C. After being washed three
times in kinase reaction buffer [12.5 mM MOPS (pH 7.5),
12.5 mM b-glycerolphosphate, 7.5 mM MgCl2, 0.5 mM
EGTA, 0.5 mM NaF, and 0.5 mM sodium vanadate] the
pellet was resuspended in 15 ml of kinase buffer and
incubated with 1 mg/ml myeline basic protein (for the
ERK assay and p38 MAPK assay) or with 0.1 mg/ml
glutathione S-transferase–c-Jun peptide (for the JNK as-
say), and 10 mCi [g-32P]ATP for 30 min at 37°C. The
reaction was terminated by addition of 15 ml of SDS–
PAGE sample buffer, and activities of ERK-1,2, JNK-1, and
p38 MAPK were detected by autoradiography after SDS–
polyacrylamide gel electrophoresis (12% gel). Experi-
ments were repeated at least three times.
Electrophoretic mobility shift assay
Nuclear extracts were prepared from HepG2 cells by
the addition of cell lysis buffer [20 mM HEPES (pH 7.9), 10
mM NaCl, 0.2 EDTA, 2 mM DTT, 1 mM Na Vanadate, and
1 mM proteinase inhibitor], and nuclei were precipitated
by centrifugation and subsequent addition of nuclear
lysis buffer [20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 1 mM
Na Vanadate, 420 mM NaCl, 0.2 EDTA, 2 mM DTT, 25%
glycerol, and 1 mM protease inhibitor]. For determination
of NF-kB signals, cells were preincubated for 12 h with
50 U/liter of IL-1. Specific oligonucleotides for binding
of AP-1 (59-CGCTTGATGACTCAGCCGGAA), Elk-1 (59-
GGATGTCCATATTAGGACATCT), ATF-2 (59-ACCACCCCT-
GACCTAACTCCG), and NF-kB (59-AGTTGAGGGGACTT-
TCCCAGGC) were prepared by end labeling of the 59-
283HCV CORE PROTEIN ACTIVATES MAP KINASESterminus with [g-32P]ATP. Reactions were performed by
incubation of 4 mg nuclear extract with 8 fmol of g-32P-
labeled oligonucleotide for 30 min at RT in a buffer
containing 5% glycerol, 2 mM MgCl2, 20 mM HEPES (pH
7.9), 0.5 mM EDTA, 0.5 mM DTT, 60 mM KCl, and 50 mg/ml
of poly(dI–dC). The DNA–protein complex was separated
from free oligonucleotide by electrophoresis on a 4%
native polyacrylamide native gel and visualized after ex-
posure to a Kodak AR X-Omat film at 270°C with inten-
sifying screens. Experiments were performed at least
three times.
Statistics
Results were compared by Student’s t test using SPSS
software (SPSS, Munich, Germany). P-values , 0.05
were considered statistically significant.
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